Superficial cells

1. Dehydroepiandrosterone increases superficial cells in humans (+8.44% over placebo).

   “the percentage of superficial cells increased by 8.44% over placebo (P < 0.0001)”

   Human trial0.50% DHEAvagina6.5 mg12 weeksfemalesn = 325

   Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

   Menopause (New York, N.Y.)·Nov 1, 2018

2. Dehydroepiandrosterone increases superficial cells in humans (+4.7% over placebo (P < 0.0001)).

   “the percentage of superficial cells increased by 4.7% over placebo (P < 0.0001)”

   Human trial0.50%vagina6.5 mg12 weeksfemales

   Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)

   Menopause (New York, N.Y.)·Sep 1, 2015

More on Dehydroepiandrosterone

1. Intravaginal estrogen increases superficial cells in humans (compared with placebo) (MD 19.28 (95% CI 13.40 to 25.16)).

   “Patients using estrogen showed a significant increase in superficial cells (mean differences [MD]: 19.28; 95% confidence intervals [CI]: 13.40 to 25.16; I2 = 90%; P < 0.00001)”

   Human trialcompared with placebointravaginalvaginafemalesn = 4,723

   Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis

   Journal of menopausal medicine·Aug 1, 2024

More on Intravaginal estrogen